Loading clinical trials...
Loading clinical trials...
The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Fujian Medical University
NCT05428969 · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, and more
NCT07026942 · Relapsed/Refractory AML
NCT04839341 · Relapsed/Refractory AML
NCT06763666 · Relapsed/Refractory AML
Fujian Medical University Union Hospital
Fuzhou, Fujian
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions